A Phase 1/2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma (MIUC) (INTerpath-005)

This study is testing a personalized cancer vaccine combined with immunotherapy to see if it can help prevent high-risk bladder cancer from coming back after surgery. By training your own immune system to recognize and attack specific cancer proteins, researchers hope to create a more effective way to keep patients cancer-free.

This trial is for individuals diagnosed with an aggressive form of bladder cancer who have already had surgery to remove the tumor. Participants must be generally healthy enough to handle their daily activities and be willing to provide blood and tumor samples for study analysis.

Participants will receive a combination of immunotherapy and a personalized cancer vaccine, or a placebo, to see how well their immune system responds. Throughout the process, the medical team will closely monitor your health and the safety of these treatments to track your progress after surgery.

The study is taking place at medical centers in Los Angeles, Orlando, and Chicago. Currently, this study is active but is not enrolling new participants.